| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/09/2004 | US20040248971 Treating prostate cancer; suppress the expression of prostate-specific antigen |
| 12/09/2004 | US20040248967 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 12/09/2004 | US20040248965 Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis |
| 12/09/2004 | US20040248954 carbocyclic sulfides such as 3-cyclohexylsulfanyl-5-methoxy-6-methyl-benzo[b]thiophene-2-carboxylic acid (1H-tetrazol-5-yl)-amide, used as phosphatidyl inositol 3-kinase inhibitors; antiinflammatory and anticarcinogenic agents; prophylaxis of cardiovascular disorders |
| 12/09/2004 | US20040248953 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
| 12/09/2004 | US20040248951 Aniline derivatives, their manufacture and use as pharmaceuticals |
| 12/09/2004 | US20040248947 N-(3- and 4-substituted phenyl)-2-(arylamino)-benzamides; aralkylation of the 2-primary amine with a benzaldehyde or a pyrid-4-yl carbaldehyde; anticarcinogenic, antitumor agents; enzyme inhibitors of vascular endothelial growth factors |
| 12/09/2004 | US20040248944 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 12/09/2004 | US20040248941 such as 4-[2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]-1,3-dioxolan-2-one, used as prodrugs to lansoprazole; proton pump inhibitors; antiulcer agents |
| 12/09/2004 | US20040248936 such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents |
| 12/09/2004 | US20040248923 Novel 4-anilinoquinoline-3-carboxamides |
| 12/09/2004 | US20040248919 Insulin sensitizers which do not increase triglyceride levels or suppress thyroid hormone axis; such as 7-[3,5-di-tert-butyl-2-(2,2-difluoroethoxy)-phenyl]-4-fluoro-3-methyl-octa-2,4,6-trienoic acid; synthesis; retinoid X receptor (rxr) |
| 12/09/2004 | US20040248915 Method for administration of troxacitabine |
| 12/09/2004 | US20040248913 (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 12/09/2004 | US20040248908 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 12/09/2004 | US20040248906 Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia |
| 12/09/2004 | US20040248897 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions |
| 12/09/2004 | US20040248896 Pyridine substituted furan derivatives as raf kinase inhibitors |
| 12/09/2004 | US20040248886 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide |
| 12/09/2004 | US20040248885 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 12/09/2004 | US20040248879 Phosphate salt of 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one; water solubility; potentiation of anticancer therapies; inhibition of neurotoxicity from stroke, head trauma and/or neurodegenerative diseases |
| 12/09/2004 | US20040248877 Inducing apoptosis in tumor cells |
| 12/09/2004 | US20040248873 Photoreactive compounds and compositions |
| 12/09/2004 | US20040248840 Oligomeric compounds for the modulation of ras expression |
| 12/09/2004 | US20040248830 Agents that regulate apoptosis |
| 12/09/2004 | US20040248820 Administering 2-phthalimidoglutaric acid; vision defects; antitumor agents; anticancer agents |
| 12/09/2004 | US20040248787 fusion protein comprising a PTD (protein transduction domain) and an MITF (microphthalmia-associated transcripution factor) variant as an active ingredient with a His tag |
| 12/09/2004 | US20040248783 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 12/09/2004 | US20040248781 Therapeutic method for reducing angiogenesis |
| 12/09/2004 | US20040248772 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration |
| 12/09/2004 | US20040248765 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 12/09/2004 | US20040248324 Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators |
| 12/09/2004 | US20040248321 Membrane protein for use in treatment and prevention of inflammatory, circulatory, cell proliferative, metabolic and immunological disorders |
| 12/09/2004 | US20040248251 Receptors and membrane associated proteins |
| 12/09/2004 | US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders |
| 12/09/2004 | US20040248243 Lipid metabolizing polypeptide for use in identifying modulators for treatment and prevention of cancer, nervous system, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 12/09/2004 | US20040248233 Using propyl hydroxylase expression system to identify modulators which interfere with or prevent generation of hypoxic states; screening modulator for treatment and prevention of cell proliferative and thrombotic disorder |
| 12/09/2004 | US20040248214 Monitoring natural killer cell activity in humans; antitumor agents; immunotherapy |
| 12/09/2004 | US20040248209 Identifying modulators which modify binding activity of isoprenoids and membrane protein receptors for use in treatment of diabetes, obesity, pain, inflamatory, cardiovascular, cancer and liver disorders |
| 12/09/2004 | US20040248208 Screening method |
| 12/09/2004 | US20040248206 Connective tissue growth factor antibodies |
| 12/09/2004 | US20040248196 Methods of screening based on the egf receptor crystal structure |
| 12/09/2004 | US20040248188 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 12/09/2004 | US20040248178 Nucleotide sequences coding neuronal outgrowth and stability protein for use in treating ovarian, renal, neurological, cell proliferative and cardiovascular disorders |
| 12/09/2004 | US20040248155 Novel oncogene, recombinant protein derived therefrom, and uses thereof |
| 12/09/2004 | US20040248137 Human and mammalian stem cell-derived neuron survival polypeptides |
| 12/09/2004 | US20040247715 Solvent extraction using water, alcohol, chloroform; antitumor, anticancer agents |
| 12/09/2004 | US20040247713 Topical anti-cancer compositions and methods of use thereof |
| 12/09/2004 | US20040247701 Fagopyrum cymosum (Trev.) meisn composition, method to prepare and analyze the same and uses thereof |
| 12/09/2004 | US20040247658 Delivery system with increased bioavailability |
| 12/09/2004 | US20040247643 A miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine |
| 12/09/2004 | US20040247621 Combination therapy using a synergistic mixture of mechlorethamine, nitrogen mustard N-oxide, melphalan, uramustin, ifosfamide, chlorambucil, or cyclophosphamide and an anti-interleukin-6 receptor antibody; anticarcinogenic agents |
| 12/09/2004 | US20040247619 Therapeutic composition including saw palmetto for cancer treatment |
| 12/09/2004 | US20040247609 Administering a non-specific immunopotentiator before administering an antigen protein ; particularly administering a cancer antigen protein, WT1, or a peptide derived from the WT1 protein in combination with a bacterium-derived component or IFN-alpha |
| 12/09/2004 | US20040247589 More particularly from the serum of alligators or crocodiles; active proteins obtained from the sera show no overt toxicity in healthy mammals, and may therefore be used for the prevention, investigation, treatment or diagnosis of cancer |
| 12/09/2004 | DE10322656A1 Pharmazeutischer Wirkstoff Active Pharmaceutical Ingredient |
| 12/09/2004 | CA2568607A1 Haloethyl urea compounds and the use thereof to attenuate, inhibit or prevent cancer cell migration |
| 12/09/2004 | CA2531319A1 Target-oriented chemotherapy for treating tumors of the sexual organs |
| 12/09/2004 | CA2527192A1 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
| 12/09/2004 | CA2527109A1 Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same |
| 12/09/2004 | CA2527017A1 Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
| 12/09/2004 | CA2526175A1 Medicament for internal application, in particular against cancerous diseases |
| 12/09/2004 | CA2525908A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| 12/09/2004 | CA2525887A1 Combined use of ecteinascidin-743 and platinum antineoplastic compounds |
| 12/09/2004 | CA2522586A1 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| 12/08/2004 | EP1484402A2 Antibody for use in therapy |
| 12/08/2004 | EP1484400A1 Sodium-independent transporter carrying acidic amino acid and its gene |
| 12/08/2004 | EP1484398A1 Human glioma antigen originating in testis |
| 12/08/2004 | EP1484397A1 Peptide from antigen MUC-1 for triggering an immune response to tumor cells |
| 12/08/2004 | EP1484338A1 Methods and compositions for inhibiting neoplastic cell growth |
| 12/08/2004 | EP1484332A2 Lipid-based drug delivery system for administration of a drug substance |
| 12/08/2004 | EP1484329A1 Indole derivatives with apoptosis inducing activity |
| 12/08/2004 | EP1484327A1 Nitrogenous heterocyclic compound and medicine thereof |
| 12/08/2004 | EP1484320A1 Jnk inhibitor |
| 12/08/2004 | EP1484319A1 Chain oligolactic acid thioester |
| 12/08/2004 | EP1484064A1 Therapeutical composition containing dentritic cells and use thereof |
| 12/08/2004 | EP1484060A2 Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 12/08/2004 | EP1484059A2 Antiviral composition comprising phenylacetic acid derivatives |
| 12/08/2004 | EP1484058A2 Pharmaceutical composition for inhibiting altering gene expression and for inducing differentiation in non-malignant cells |
| 12/08/2004 | EP1484055A1 Delivery system with increased bioavailability |
| 12/08/2004 | EP1484054A1 Drug delivery system for the subconjunctival administration of fine grains |
| 12/08/2004 | EP1483389A2 Genetic products differentially expressed in tumors and use thereof |
| 12/08/2004 | EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo |
| 12/08/2004 | EP1483297A2 Antibodies derived from anti ed-b l19 and targeting tumor vasculature |
| 12/08/2004 | EP1483296A1 Specific ab1'-antibodies against tumour-associated antigen ca 125 |
| 12/08/2004 | EP1483294A2 Internalizing anti-cd74 antibodies and methods of use |
| 12/08/2004 | EP1483290A2 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 12/08/2004 | EP1483289A2 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 12/08/2004 | EP1483284A2 Selective dipeptide inhibitors of kallikrein |
| 12/08/2004 | EP1483268A2 Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| 12/08/2004 | EP1483267A2 Microtubule stabilizing compounds |
| 12/08/2004 | EP1483263A1 Thiazolyl urea compounds for the treatment of cancer |
| 12/08/2004 | EP1483261A1 Phthalimide carboxylic acid derivatives |
| 12/08/2004 | EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
| 12/08/2004 | EP1483251A1 C3-cyano epothilone derivatives |
| 12/08/2004 | EP1483244A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase |
| 12/08/2004 | EP1483233A2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
| 12/08/2004 | EP1482988A1 METHOD OF RADIO−LABELLING BIOMOLECULES |
| 12/08/2004 | EP1482984A2 Surrogate antibodies and methods of preparation and use thereof |
| 12/08/2004 | EP1482983A2 Non-myeloablative tolerogenic treatment with tyrphostins |